FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
1-Year Return
23.12%
This Quarter Return
+22.03%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$13B
AUM Growth
+$753M
(+6.2%)
Cap. Flow
-$1.82B
Cap. Flow
% of AUM
-13.99%
Top 10 Holdings %
Top 10 Hldgs %
41.93%
Holding
132
New
29
Increased
37
Reduced
29
Closed
15
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$336M |
| 2 |
MDCO
Medicines Co
MDCO
|
$282M |
| 3 |
Salesforce
CRM
|
$281M |
| 4 |
Thermo Fisher Scientific
TMO
|
$277M |
| 5 |
IAC Inc
IAC
|
$152M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$1.55B |
| 2 |
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
|
$865M |
| 3 |
AABA
Altaba Inc. Common Stock
AABA
|
$666M |
| 4 |
Alibaba
BABA
|
$221M |
| 5 |
CTXS
Citrix Systems Inc
CTXS
|
$183M |
Sector Composition
| 1 | Healthcare | 43.93% |
| 2 | Communication Services | 12.69% |
| 3 | Technology | 11.19% |
| 4 | Industrials | 5.73% |
| 5 | Financials | 4.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
S&P Global
SPGI
$164B
| $175M | 1.18% |
640,382
-191,932
| -23% | -$52.4M |
|
27
General Dynamics
GD
$86.8B
| $173M | 1.17% |
981,365
-10,367
| -1% | -$1.83M |
|
28
Iovance Biotherapeutics
IOVA
$901M
| $173M | 1.17% |
6,250,000
+225,000
| +4% | +$6.23M |
|
29
Alnylam Pharmaceuticals
ALNY
$59.2B
| $167M | 1.13% |
1,450,000
-50,000
| -3% | -$5.76M |
|
|
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $149M | 1.01% |
2,050,000
+19,603
| +1% | +$1.43M |
|
31
Exelixis
EXEL
$10.2B
| $132M | 0.89% |
7,500,000
+5,750,000
| +329% | +$101M |
|
32
TransUnion
TRU
$17.5B
| $131M | 0.88% |
1,527,771
+272,633
| +22% | +$23.3M |
|
33
Enanta Pharmaceuticals
ENTA
$189M
| $108M | 0.73% |
1,750,000
+475,788
| +37% | +$29.4M |
|
|
XLRN
34
DELISTED
Acceleron Pharma Inc.
XLRN
| $106M | 0.72% |
2,000,000
-400,000
| -17% | -$21.2M |
|
|
BRMK
35
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $91.5M | 0.62% |
7,174,613
-67,825,387
| -90% | -$865M |
|
|
BMY.RT
36
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $91.4M | 0.62% |
+30,374,950
| New | +$91.4M |
|
37
Equifax
EFX
$30.8B
| $91.4M | 0.62% |
652,189
+17,133
| +3% | +$2.4M |
|
|
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
| $91.2M | 0.62% |
1,750,000
| – | – |
|
|
AMRN
39
Amarin Corp
AMRN
$317M
| $88.4M | 0.6% |
206,250
+106,220
| +106% | +$45.5M |
|
|
AXE
40
DELISTED
Anixter International Inc
AXE
| $84.5M | 0.57% |
+917,893
| New | +$84.5M |
|
41
Zymeworks
ZYME
$1.14B
| $77.3M | 0.52% |
1,700,000
-31,500
| -2% | -$1.43M |
|
42
Qiagen
QGEN
$10.3B
| $72.8M | 0.49% |
+2,031,342
| New | +$72.8M |
|
43
Grifois
GRFS
$6.89B
| $72.5M | 0.49% |
3,113,222
| – | – |
|
|
BOLD
44
DELISTED
Audentes Therapeutics, Inc
BOLD
| $71.2M | 0.48% |
+1,190,000
| New | +$71.2M |
|
45
Agios Pharmaceuticals
AGIO
$2.09B
| $59.7M | 0.4% |
+1,250,000
| New | +$59.7M |
|
|
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $59.6M | 0.4% |
750,000
-862,069
| -53% | -$68.5M |
|
|
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
| $59.3M | 0.4% |
1,500,000
-513,396
| -25% | -$20.3M |
|
|
DCPH
48
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $59.1M | 0.4% |
950,000
+200,000
| +27% | +$12.4M |
|
49
FibroGen
FGEN
$48.9M
| $57.9M | 0.39% |
54,000
+14,000
| +35% | +$15M |
|
|
RARX
50
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $55.8M | 0.38% |
+1,188,100
| New | +$55.8M |
|